A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma — Stella
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
(82 sites) United States
Local Institution - 307, Stanford, California Local Institution - 0305, Aurora, Colorado Local Institution - 305, Aurora, Colorado Local Institution - 308, Tampa, Florida Moffitt Cancer Center, Tampa, Florida Local Institution - 0311, Chicago, Illinois Local Institution - 311, Chicago, Illinois Local Institution - 314, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, Massachusetts Local Institution - 313, Boston, Massachusetts Local Institution - 316, St Louis, Missouri Washington University School of Medicine in St. Louis, St Louis, Missouri Local Institution - 0315, New Brunswick, New Jersey Local Institution - 315, New Brunswick, New Jersey Local Institution - 310, Buffalo, New York Roswell Park Comprehensive Cancer Center, Buffalo, New York Local Institution - 301, New York, New York Memorial Sloan Kettering Cancer Center, New York, New York Cleveland Clinic, Cleveland, Ohio Local Institution - 302, Cleveland, Ohio Local Institution - 309, Columbus, Ohio The Ohio State University Comprehensive Cancer Center, Columbus, Ohio Local Institution - 304, Philadelphia, Pennsylvania University of Pennsylvania, Philadelphia, Pennsylvania Local Institution - 312, Nashville, Tennessee Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee Local Institution - 0303, Houston, Texas Local Institution - 303, Houston, Texas Fred Hutchinson Cancer Center, Seattle, Washington Local Institution - 306, Seattle, Washington France
Local Institution - 0111, Nice, Alpes-Maritimes Local Institution - 111, Nice, Alpes-Maritimes Local Institution - 0104, Nantes, Loire-Atlantique Local Institution - 104, Nantes, Loire-Atlantique Local Institution - 0103, Pierre-BĂ©nite, RhĂ´ne Local Institution - 0106, Dijon Local Institution - 106, Dijon Local Institution - 0113, Lille Local Institution - 113, Lille Local Institution - 0112, Marseille Local Institution - 112, Marseille Local Institution - 0107, Montpellier Local Institution - 107, Montpellier Local Institution - 0114, Paris Germany
Local Institution - 0202, Freiburg im Breisgau, Baden-Wurttemberg Local Institution - 205, Ulm, Baden-Wurttemberg Universitätsklinikum Ulm, Ulm, Baden-Wurttemberg Local Institution - 0204, Cologne, North Rhine-Westphalia Local Institution - 204, Cologne, North Rhine-Westphalia Local Institution - 0206, Essen, North Rhine-Westphalia Local Institution - 206, Essen, North Rhine-Westphalia Klinikum Chemnitz gGmbH, Chemnitz, Saxony Local Institution - 208, Chemnitz, Saxony Charité - Universitätsmedizin Berlin, Berlin Local Institution - 203, Berlin Local Institution - 202, Freiburg im Breisgau Local Institution - 0207, Göttingen
Key details Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Enrollment target
~65 participants
Primary completion
January 2028
Age range
18 Years and older
Last updated March 2026
Local Institution - 114, Paris Local Institution - 0102, Paris Local Institution - 102, Paris Local Institution - 0108, Pessac Local Institution - 108, Pessac Local Institution - 103, Pierre-Bénite CHU de Rennes - Hopital de Pontchaillou, Rennes Local Institution - 101, Rennes Local Institution - 0105, Rouen Local Institution - 105, Rouen Local Institution - 0110, Saint-Cloud Local Institution - 110, Saint-Cloud Local Institution - 0115, Strasbourg Local Institution - 115, Strasbourg Local Institution - 0109, Toulouse Local Institution - 109, Toulouse Local Institution - 0116, Vandœuvre-lès-Nancy Local Institution - 116, Vandœuvre-lès-Nancy Local Institution - 207, Göttingen
Local Institution - 209, Hamburg Universitätsklinikum Hamburg-Eppendorf, Hamburg Local Institution - 210, Heidelberg Universitätsklinikum Heidelberg, Heidelberg Klinikum Stuttgart - Katharinenhospital, Stuttgart Local Institution - 201, Stuttgart
Interested in joining?